Although the diagnosis of dementia is still largely a clinical one, based on history and
disease course, neuroimaging has dramatically increased our ability to accurately diagnose …

Amyloid-β (Aβ) PET imaging has now been available for over 15 years. The ability to detect
Aβ in vivo has greatly improved the clinical and research landscape of Alzheimer's disease …

Although diagnosing the syndrome of dementia is largely a clinical endeavor, neuroimaging
plays an increasingly important role in accurately determining the underlying etiology, which …

Dementia is a global health issue, the burden of which will worsen with an increasingly
aging population. Alzheimer's disease (AD) is the most common dementia, with 50 to 60% of …

Although it afflicts an estimated 26.6 million people worldwide—a figure that is expected to
quadruple by 2050—Alzheimer's disease (AD) has yet to be fully understood etiologically …

The precise role of environment‐gene interactions (epigenetics) in the development and
progression of Alzheimer's disease (AD) is unclear. This review focuses on the premise that …

Alzheimer's disease (AD) is a devastating and progressive neurodegenerative disease for
which there is no cure. Mild cognitive impairment (MCI) is considered a prodromal stage of …

The neurodegenerative disorder Alzheimer's disease (AD) is the most common form of
dementia. It is characterized by progressive impairment of cognitive functions and behavior …

Molecular neuroimaging techniques such as PET are proving valuable in the early and
differential diagnosis of Alzheimer's disease (AD). With the advent of new therapeutic …

Alzheimer's disease (AD) is a major public health problem affecting nearly 35 million people
worldwide with numbers projected to rise to 115.4 million by 2050. Medicare and Medicaid …